RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Blokhin Russian Cancer Research Center

Company

Content

Number of employees
2017 year
3500

Owners

FSBI "National Medical Research Center of Oncology named after N.N. Blokhin" Ministry of Health Russia is the successor to the Academy of Medical Sciences of the USSR, created by the Decree of the Council of Ministers of the USSR of October 22, 1951.

N.N. Blokhin National Medical Research Center of Oncology has three branches: the Altai branch in Barnaul, the Volga branch in the Republic of Tatarstan and the Scientific and Production branch of Naukoprofi, located in Moscow. On the basis of the center there are 8 departments of medical academies and universities.

The structure of the center includes five divisions:

  • Research Institute of Clinical Oncology (for adult patients), designed for 850 beds
  • Research Institute of Pediatric Oncology and Hematology, designed for 150 beds
  • Research Institute of Clinical and Experimental Radiology, designed for 50 beds
  • Carcinogenesis Research Institute, comprising 16 laboratories
  • Research Institute for Experimental Diagnosis and Therapy of Tumors, including 15 laboratories

The main activities are:

  • providing highly qualified medical care to patients with malignant neoplasms and pre-neoplastic pathology;
  • conducting scientific research in the field of studying the biology of a tumor cell, the mechanisms of carcinogenesis and tumor progression (molecular, virological, chemical-physical, genetic, cellular, immunological aspects);
  • experimental and clinical development of new technologies in the field of surgical treatment of malignant tumors;
  • development of new diagnostic products and methods, drug, radiation and combination therapy, as well as active tumor prevention;
  • development of issues of diagnosis, treatment and prevention in the field of pediatric oncology;
  • studying the epidemiology of malignant tumors, improving methods of oncological statistics;
  • introduction of new devices and technologies in the medical and diagnostic process and for the prevention of malignant neoplasms;
  • training of scientific and medical personnel through residency, postgraduate studies, doctoral studies and in the system of additional professional education.

Employees of the center conduct extremely significant research in the field of experimental and clinical oncology. The center presents all existing types of cancer care.

History

2024: Obtaining expensive CAR-T therapy equipment

The National Medical Research Center (NMSC) of Oncology named after N.N. Blokhin completed the installation and put into operation expensive equipment for the production of CAR-T cells. This became known on September 26, 2024.

According to Medvestnik, the complex of equipment for cell selection and separation, as well as the installation of "clean" rooms were funded by the Life Line charitable foundation. The exact amount of investment and equipment brands were not disclosed. It is only known that suppliers represent different countries: Germany, China and Russia.

Blokhin National Medical Research Center received new equipment for CAR-T therapy

CAR-T therapy is an innovative method of treating cancer in which the patient is administered his own modified T lymphocytes. These cells are equipped with a chimeric receptor capable of recognizing target tumor cells. The method is especially effective in the treatment of aggressive forms of non-Hodgkin lymphoma and acute lymphoblastic leukemia that do not respond to standard therapy.

Nara Stepanyan, a transfusiologist at the Research Institute of Pediatric Oncology and Hematology of the National Medical Research Center, said that CAR-T therapy will be used to treat children with cancer who have palliative status or advanced relapse after standard chemotherapy. According to her, in the first year it is planned to treat about 20 children.

Experts note that about 4 thousand cases of cancer in children are diagnosed annually in Russia. CAR-T therapy can be a rescue for about 10% of underage patients who do not respond to standard treatment.

The Blokhin National Medical Research Center plans to begin using the method by the end of this year, after receiving the necessary documentation for the operation of equipment. In the future, the center's specialists are considering the possibility of using CAR-T cells to treat solid tumors, including congenital tumors of the kidneys and bones.[1]

2023: Participation in photosensitive agent trials for photodynamic cancer therapy

A team of scientists from NUST MISIS, Sechenov University and N.N. Blokhin National Medical Research Center of Oncology presented the results of testing a photosensitive substance for photodynamic therapy of cancer - a photosensitizer (PS) of bacteriochlorine. MISIS University announced this on July 18, 2023. Read more here.